Toolkit for Immunotherapy IV to SC switch
Dear all,
In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however, it also presents logistical challenges for SACT providers, particularly within pharmacy services.
To support members in navigating this transition, where appropriate, the BOPA Immunotherapy Specialist Advisory Group has developed a straightforward toolkit designed to assist with implementation.
The toolkit is available for both BOPA free and paid associates HERE.
Best wishes,
BOPA IO SAG
